DOI:
10.1055/s-00000075
Seminars in Respiratory and Critical Care Medicine
LinksClose Window
References
Bernstein JA, Virchow JC, Murphy K. et al.
Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials.
Lancet Respir Med 2020;
8 (05) 461-474
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.